Cargando…
Appropriate radiation dose for symptomatic relief and local control in patients with adult T cell leukemia/lymphoma
Adult T-cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell neoplasm that occurs only in patients with human T-cell leukemia virus type 1. No large study or randomized trial investigating radiotherapy (RT) for ATL has been performed. We retrospectively reviewed 55 courses of RT for 41 co...
Autores principales: | Maemoto, Hitoshi, Ariga, Takuro, Nakachi, Sawako, Toita, Takafumi, Hashimoto, Seiji, Heianna, Joichi, Shiina, Hideki, Kusada, Takeaki, Makino, Wataru, Kakinohana, Yasumasa, Miyagi, Takuya, Yamamoto, Yuichi, Morishima, Satoko, Masuzaki, Hiroaki, Murayama, Sadayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373688/ https://www.ncbi.nlm.nih.gov/pubmed/30124892 http://dx.doi.org/10.1093/jrr/rry068 |
Ejemplares similares
-
Computed tomography–based image-guided brachytherapy for cervical cancer: correlations between dose–volume parameters and clinical outcomes
por: Kusada, Takeaki, et al.
Publicado: (2018) -
Definitive radiotherapy consisting of whole pelvic radiotherapy with no central shielding and CT-based intracavitary brachytherapy for cervical cancer: feasibility, toxicity, and oncologic outcomes in Japanese patients
por: Kusada, Takeaki, et al.
Publicado: (2020) -
Predictive factors of posttreatment fracture by definitive radiotherapy for uterine cervical cancer
por: Ishikawa, Kazuki, et al.
Publicado: (2020) -
Correction to: Definitive radiotherapy consisting of whole pelvic radiotherapy with no central shielding and CT-based intracavitary brachytherapy for cervical cancer: feasibility, toxicity, and oncologic outcomes in Japanese patients
por: Kusada, Takeaki, et al.
Publicado: (2023) -
Predictive factors of uterine movement during definitive radiotherapy for cervical cancer
por: Maemoto, Hitoshi, et al.
Publicado: (2017)